Convection-Enhanced delivery of neprilysin: A novel amyloid-β- degrading therapeutic strategy

Journal of Alzheimer's Disease

Volumn 32, Issue 1, 2012, Pages 43-56

  Barua, Neil U ^a   Miners, J Scott ^a   Bienemann, Alison S ^a   Wyatt, Marcella J ^a   Welser, Katharina ^b   Tabor, Alethea B ^b   Hailes, Helen C ^b   Love, Seth ^a   Gill, Steven S ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; amyloid ; convection enhanced delivery; neprilysin; therapy

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; NEURON SPECIFIC NUCLEAR PROTEIN; SYNAPTOPHYSIN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN TISSUE; COGNITION; CONTROLLED STUDY; CONVECTION ENHANCED DELIVERY SYSTEM; CORPUS STRIATUM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANALYSIS; GENE DELIVERY SYSTEM; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; RAT;

EID: 84867527566     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120658     Document Type: Article

References (50)

1. Shah NS, Vidal JS, Masaki K, Petrovitch H, Ross GW, Tilley C, DeMattos RB, Tracy RP, White LR, Launer LJ (2012) Midlife blood pressure, plasma beta-amyloid, and the risk for Alzheimer disease: The Honolulu Asia Aging Study. Hypertension 59, 780-786.
2. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506.
3. Kurz A, Perneczky R (2011) Amyloid clearance as a treatment target against Alzheimer's disease. J Alzheimers Dis 24 (Suppl 2), 61-73.
4. Miners JS, Barua N, Kehoe PG, Gill S, Love S (2011) Abetadegrading enzymes: Potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 70, 944-959.
5. Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ (2012) Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? J Neurochem 120(Suppl 1), 167-185.
6. Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, Kiryu-Seo S, Kiyama H, Iwata H, Tomita T, Iwatsubo T, Saido TC (2001) Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J Biol Chem 276, 21895-21901.
7. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-AizawaY, Saido TC (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med 6, 143-150.
8. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC (2001) Metabolic regulation of brain Abeta by neprilysin. Science 292, 1550-1552.
9. Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, NodaY,Yamaguchi H, Nabeshima T, Saido TC, Iwata N (2006) Neprilysin-sensitive synapseassociated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 281, 17941-17951.
10. Madani R, Poirier R, Wolfer DP, Welzl H, Groscurth P, Lipp HP, Lu B, ElMouedden M, Mercken M, Nitsch RM, Mohajeri MH (2006) Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J Neurosci Res 84, 1871-1878.
11. FarrisW, Schutz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA,Walsh DM, QiuWQ,Holtzman DM, Selkoe DJ (2007) Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 171, 241-251.
12. Leissring MA, FarrisW, ChangAY,Walsh DM,WuX, Sun X, Frosch MP, Selkoe DJ (2003) Enhanced proteolysis of betaamyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093.
13. Poirier R,WolferDP,Welzl H,Tracy J, GalsworthyMJ, Nitsch RM, Mohajeri MH (2006) Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit. Neurobiol Dis 24, 475-483.
14. Spencer B, Marr RA, Rockenstein E, Crews L, Adame A, Potkar R, Patrick C, Gage FH, Verma IM, Masliah E (2008) Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice. BMC Neurosci 9, 109.
15. White E, Bienemann A, Megraw L, Bunnun C, Wyatt M, Taylor H, Gill S (2012) Distribution properties of lentiviral vectors administered into the striatum by convectionenhanced delivery. Hum Gene Ther 23, 115-127.
16. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91, 2076-2080.
17. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9, 589-595.
18. Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, Sherman JW, Husain SR, Puri RK (2007) Convection-enhanced delivery of cintredekin besudotox (interleukin-13-Pe38qqr) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: Phase 1 study of final safety results. Neurosurgery 61, 1031-1037.
19. Bruce JN, Fine RL, Canoll P, Yun J, Kennedy BC, Rosenfeld SS, Sands SA, Surapaneni K, Lai R, Yanes CL, Bagiella E, Delapaz RL (2011) Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 69, 1272-1279.
20. Barua NU, Bienemann AS, Hesketh S, Wyatt MJ, Castrique E, Love S, Gill SS (2012) Intrastriatal convectionenhanced delivery results in widespread perivascular distribution in a pre-clinical model. Fluids Barriers CNS 9, 2.
21. White E, Bienemann A, Malone J, Megraw L, Bunnun C, Wyatt M, Gill S (2011) An evaluation of the relationships between catheter design and tissue mechanics in achieving high-flow convection-enhanced delivery. J Neurosci Methods 199, 87-97.
22. Miners JS, van Helmond Z, Kehoe PG, Love S (2010) Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. Brain Pathol 20, 794-802.
23. Miners JS, Baig S, Tayler H, Kehoe PG, Love S (2009) Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J Neuropathol Exp Neurol 68, 902-914.
24. Miners JS, Verbeek MM, Rikkert MO, Kehoe PG, Love S (2008) Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. J Neurosci Methods 167, 229-236.
25. Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS (2005) Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 11, 703-704.
26. Siew LK, Love S, Dawbarn D,Wilcock GK, Allen SJ (2004) Measurement of pre- and post-synaptic proteins in cerebral cortex: Effects of post-mortem delay. J Neurosci Methods 139, 153-159.
27. van Helmond Z, Miners JS, Kehoe PG, Love S (2010) Oligomeric Abeta in Alzheimer's disease: Relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. Brain Pathol 20, 468-480.
28. Schley D, Carare-Nnadi R, Please CP, Perry VH, Weller RO (2006) Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J Theor Biol 238, 962-974.
29. Saito R, Krauze MT, Noble CO, Tamas M, Drummond DC, Kirpotin DB, Berger MS, Park JW, Bankiewicz KS (2006) Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: Implications for local drug delivery. J Neurosci Methods 154, 225-232.
30. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342.
31. Hamaguchi T, Ono K, YamadaM(2006) Anti-amyloidogenic therapies: Strategies for prevention and treatment of Alzheimer's disease. Cell Mol Life Sci 63, 1538-1552.
32. Hull M, Berger M, HenekaM(2006) Disease-modifying therapies in Alzheimer's disease: How far have we come? Drugs 66, 2075-2093.
33. Estrada LD, Soto C (2007) Disrupting beta-amyloid aggregation for Alzheimer disease treatment. Curr Top Med Chem 7, 115-126.
34. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
35. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide:Acase report. Nat Med 9, 448-452.
36. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562.
37. Guan H, Liu Y, Daily A, Police S, Kim MH, Oddo S, LaFerla FM, Pauly JR, Murphy MP, Hersh LB (2009) Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's disease. J Neurosci Res 87, 1462-1473.
38. Spencer B, Marr RA, Gindi R, Potkar R, Michael S, Adame A, Rockenstein E, Verma IM, Masliah E (2011) Peripheral delivery of a CNS targeted, metalo-protease reduces abeta toxicity in a mouse model of Alzheimer's disease. Plos One 6, e16575.
39. Goodman OB Jr, Febbraio M, Simantov R, Zheng R, Shen R, Silverstein RL, Nanus DM (2006) Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. J Biol Chem 281, 33597-33605.
40. Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM, Masliah E (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 23, 1992-1996.
41. Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, Gerard NP, Gerard C, Ozawa K, Saido TC (2004) Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci 24, 991-998.
42. Lowenstein PR, Mandel RJ, Xiong WD, Kroeger K, Castro MG (2007) Immune responses to adenovirus and adenoassociated vectors used for gene therapy of brain diseases: The role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther 7, 347-360.
43. El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS (2008) Neprilysin: An enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol 172, 1342-1354.
44. White E, Bienemann A, Sena-EstevesM,Taylor H, Bunnun C, Castrique E, Gill S (2011) Evaluation and optimization of the administration of recombinant adeno-associated viral vectors (serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by convectionenhanced delivery to the striatum. Hum Gene Ther 22, 237-251.
45. Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, Kawakami T, Urabe M, Kume A, Sato T,Watanabe E, Ozawa K, Nakano I (2010) A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 18, 1731-1735.
46. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS (2005) Intraputamenal infusion of glial cell linederived neurotrophic factor in PD:Atwo-year outcome study. Ann Neurol 57, 298-302.
47. Chiu C, Miller MC, Caralopoulos IN,Worden MS, Brinker T, Gordon ZN, Johanson CE, Silverberg GD (2012) Temporal course of cerebrospinal fluid dynamics and amyloid accumulation in the aging rat brain from three to thirty months. Fluids Barriers CNS 9, 3.
48. Bienemann A, White E,WoolleyM, Castrique E, Johnson DE, Wyatt M, Murray G, Taylor H, Barua N, Gill SS (2012) The development of an implantable catheter system for chronic or intermittent convection-enhanced delivery. J Neurosci Methods 203, 284-291.
49. Grothe M, Heinsen H, Teipel SJ (2012) Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer's disease. Biol Psychiatry 71, 805-813.
50. Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, Olson L, Seiger, Shigeta M, Theodorsson E, Viitanen M, Winblad B, Wahlund LO (1998) Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 9, 246-257.